These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10321537)

  • 1. Systemic bioavailability of ocularly applied 1% atropine eyedrops.
    Kaila T; Korte JM; Saari KM
    Acta Ophthalmol Scand; 1999 Apr; 77(2):193-6. PubMed ID: 10321537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
    Korte JM; Kaila T; Saari KM
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical ophthalmic atropine in horses, pharmacokinetics and effect on intestinal motility.
    Ström L; Dalin F; Domberg M; Stenlund C; Bondesson U; Hedeland M; Toutain PL; Ekstrand C
    BMC Vet Res; 2021 Apr; 17(1):149. PubMed ID: 33827566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Objective evaluation of the systemic effects of topical application of 1% atropine sulfate ophthalmic solution in healthy horses.
    Wehrman RF; Gemensky-Metzler AJ; Zibura AE; Nyhart AB; Chandler HL
    J Am Vet Med Assoc; 2017 Dec; 251(11):1324-1330. PubMed ID: 29154707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study.
    Kentala E; Kaila T; Iisalo E; Kanto J
    Int J Clin Pharmacol Ther Toxicol; 1990 Sep; 28(9):399-404. PubMed ID: 2228327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The penetration and distribution of topical atropine in animal ocular tissues.
    Wang LZ; Syn N; Li S; Barathi VA; Tong L; Neo J; Beuerman RW; Zhou L
    Acta Ophthalmol; 2019 Mar; 97(2):e238-e247. PubMed ID: 30259687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
    Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
    Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic absorption of topically applied ocular atropine.
    Lahdes K; Kaila T; Huupponen R; Salminen L; Iisalo E
    Clin Pharmacol Ther; 1988 Sep; 44(3):310-4. PubMed ID: 3046815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic adverse effects of topical ocular treatments.
    Labetoulle M; Frau E; Le Jeunne C
    Presse Med; 2005 Apr; 34(8):589-95. PubMed ID: 15962500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma concentration of topically applied betaxolol in elderly glaucoma patients.
    Vainio-Jylhä E; Vuori ML; Pyykkö K; Huupponen R
    J Ocul Pharmacol Ther; 2001 Jun; 17(3):207-13. PubMed ID: 11436941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel.
    Uusitalo H; Niño J; Tahvanainen K; Turjanmaa V; Ropo A; Tuominen J; Kähönen M
    Acta Ophthalmol Scand; 2005 Dec; 83(6):723-8. PubMed ID: 16396651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2).
    Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D
    Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing systemic absorption of topically administered ophthalmic drugs.
    Urtti A; Salminen L
    Surv Ophthalmol; 1993; 37(6):435-56. PubMed ID: 8100087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atropine Eye Drops: A Proposed Field Expedient Substitute in the Absence of Atropine Autoinjectors.
    Calvano CJ; Enzenauer RW; Eisnor DL; Mazzoli RA
    J Spec Oper Med; 2017; 17(3):81-83. PubMed ID: 28910474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine.
    Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH
    Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atropine treatment for myopia.
    Brown SM
    Ophthalmology; 2009 Oct; 116(10):2040; author reply 2040-1. PubMed ID: 19800530
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of intravenous and endobronchial atropine: a pharmacokinetic and -dynamic study in pigs.
    Hörnchen U; Schüttler J; Stoeckel H; Ensing K; de Zeeuw RA; Eichelkraut W
    Eur J Anaesthesiol; 1989 Mar; 6(2):95-101. PubMed ID: 2721508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.